Autolus Therapeutics plc (AUTL: NASDAQ) Investor Relations Material

Overview

Autolus Therapeutics plc, a UK-based clinical-stage biopharmaceutical company, is changing the game in cancer treatment. The company is currently developing T cell therapies that are designed to target and eradicate cancer cells. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that's currently in Phase 1b/2 clinical trials for the treatment of adult acute lymphoblastic leukemia (ALL). Additionally, Autolus is developing AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL. The company is also working on AUTO4, a programmed T cell investigational therapy that targets TRBC1 and TRBC2 for the treatment of peripheral T-cell lymphoma. Furthermore, they are developing AUTO6NG, a programmed T cell investigational therapy that targets GD2, which is currently in preclinical trials for the treatment of neuroblastoma. Lastly, the company's product candidate AUTO8 is in a Phase I clinical trial for multiple myeloma. Autolus is also working on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was founded in 2014 and is currently headquartered in London, UK.